MikeKonner
Long

MYGN Earnings Oversold Play

NASDAQ:MYGN   MYRIAD GENETICS INC
MYGN             took a beating after it's guidance underwhelm last quarter.
I do believe that the reaction was overdone.

MYGN             has healthy revenue streams and growing drug and generics demand.

TA confirms a re-entering into trading range of:
PT 1: $25.00 for a ~20%+ return.
PT 2: $30.00 for a 50% return.
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out